A case series of low dose bevacizumab and chemotherapy in heavily pretreated patients with epithelial ovarian cancer

被引：0
|
作者：
Carlotta Defferrari
Sara Campora
Mauro D'Amico
Arnoldo Piccardo
Ennio Biscaldi
Daniela Rosselli
Ambra Pasa
Matteo Puntoni
Alberto Gozza
Alessandra Gennari
Silvia Zanardi
Rita Lionetto
Michela Bandelloni
Andrea DeCensi
机构：
[1] E.O. Ospedali Galliera,Unit of Medical Oncology
[2] E.O. Ospedali Galliera,Nuclear Medicine
[3] E.O. Ospedali Galliera,Radiology
[4] E.O. Ospedali Galliera,Gynecology
[5] E.O. Ospedali Galliera,Scientific Direction
[6] E.O. Ospedali Galliera,Health Direction
[7] E.O. Ospedali Galliera,Pharmacy
来源：
Journal of Ovarian Research | / 5卷
关键词：
Bevacizumab; Standardize Uptake Value; Epithelial Ovarian Cancer; Diabetic Macular Edema; Weekly Paclitaxel;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer
    Zhai, Xiaoyu
    Hong, Ruoxi
    Fan, Ying
    Yuan, Peng
    Wang, Jiayu
    Sang, Die
    Chen, Junlin
    Zhao, Chunying
    Ou, Kaiping
    Ma, Fei
    Xu, Binghe
    THORACIC CANCER, 2018, 9 (05) : 613 - 620
  • [32] Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
    O'Malley, David M.
    Richardson, Debra L.
    Rheaume, Patrick S.
    Salani, Ritu
    Eisenhauer, Eric L.
    McCann, Georgia A.
    Fowler, Jeffrey M.
    Copeland, Larry J.
    Cohn, David E.
    Backes, Floor J.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (02) : 269 - 272
  • [33] Salvage therapy with topotecan in heavily pretreated ovarian cancer patients
    Bodnar, Lubomir
    Wcislo, Gabriel
    Nasilowska, Anna
    Szarlej-Wcislo, Katarzyna
    Gasowska-Bodnar, Agnieszka
    Smoter, Marta
    Szczylik, Cezary
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (06) : 815 - 821
  • [34] Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
    Markman, Maurie
    GYNECOLOGIC ONCOLOGY, 2012, 124 (01) : 171 - 171
  • [35] Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated, recurrent epithelial ovarian cancer
    Hurt, J.
    Backes, F.
    Rheaume, S.
    Richardson, D.
    Fowler, J.
    Copeland, L.
    Cohn, D.
    Eisenhauer, E.
    Salani, R.
    O'Malley, D.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S47 - S47
  • [36] Salvage therapy with topotecan in heavily pretreated ovarian cancer patients
    Lubomir Bodnar
    Gabriel Wcislo
    Anna Nasilowska
    Katarzyna Szarlej-Wcislo
    Agnieszka Gasowska-Bodnar
    Marta Smoter
    Cezary Szczylik
    Journal of Cancer Research and Clinical Oncology, 2009, 135
  • [37] Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients
    Bilgin, T
    Özalp, S
    Yalçin, ÖT
    Zorlu, G
    Vardar, MA
    Özerkan, K
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2003, 24 (02) : 169 - 170
  • [38] Topotecan in heavily pretreated platinum resistant ovarian cancer patients
    Aravantinos, G
    Zafiropoulos, A
    Bafaloukos, D
    Samantas, E
    Janinis, J
    Papakostas, P
    Sikiotis, A
    Kiamouris, C
    Rapsomaniki, T
    Skarlos, DV
    ANNALS OF ONCOLOGY, 1998, 9 : 67 - 67
  • [39] Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer
    Chollet, P
    Bensmaine, MA
    Brienza, S
    Deloche, C
    Cure, H
    Caillet, H
    Cvitkovic, E
    ANNALS OF ONCOLOGY, 1996, 7 (10) : 1065 - 1070
  • [40] Safety and efficacy of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast
    Fedele, P.
    Orlando, L.
    Schiavone, P.
    Rizzo, P.
    Calvani, N.
    D'Amico, M.
    Marino, A.
    Sponziello, F.
    Cinieri, A. Nacci e S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345